Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US pharma pay-for-delay deals could live to fight another day

This article was originally published in SRA

Executive Summary

If the US Supreme Court decides that reverse-settlement agreements between innovator drug makers and generic firms are violations of law, then patents and intellectual property rights would be devalued, with patent holders and challengers left spending time and resources fighting litigation to judgment – a losing scenario for everybody, insisted Washington lawyer Diane Bieri, a partner at Arnold and Porter.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel